Ad-RTS-hIL-12 + veledimex + cemiplimab-rwlc

Ad-RTS-hIL-12 + veledimex + cemiplimab-rwlc is a combination investigational regimen consisting of three components: Ad-RTS-hIL-12, veledimex, and cemiplimab-rwlc. - Ad-RTS-hIL-12 is a gene therapy that delivers the gene for human interleukin-12 (IL-12) via an inducible adenoviral vector, with its expression controlled by the RheoSwitch Therapeutic System gene switch, which is responsive to veledimex. - Veledimex is a small molecule oral activator ligand that induces the expression of IL-12 from Ad-RTS-hIL-12, enabling dose- and duration-dependent control over IL-12 production[1][3][9]. - Cemiplimab-rwlc is a monoclonal antibody targeting programmed death receptor-1 (PD-1), serving as an immune checkpoint inhibitor, approved for indications including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer[2][5][8]. In this combined regimen, the goal is to induce localized and controllable expression of IL-12 in the tumor microenvironment to stimulate immune activation, while cemiplimab-rwlc provides systemic immune checkpoint blockade, together enhancing anti-tumor immune responses. This approach is being tested primarily in recurrent or progressive glioblastoma and other advanced solid tumors[3][9].

Brand names

Libtayo

Other names

Ad-RTS-hIL-12Ad-RTS-hIL12Ad-RTS-hIL 12veledimexLibtayo